How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,850 results for

Mobile Medical Applications

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8781. Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

. Then, the cells are collected by apheresis. In this procedure the blood is drawn through a needle placed in one arm and pumped into a machine where the stem cells are separated out and removed. The rest of the blood is returned to the donor through a needle in the other arm. Patients: For patients who do not already have a central venous catheter (plastic tube), one is placed into a major vein. This tube can stay in the body the entire treatment period for giving medications, transfusing blood, , withdrawing (...) and mount an immune response against them. After hospital discharge, patients are followed in the clinic at least once or twice weekly for a medical history, physical exam, and blood tests for 100 days. They receive medications to prevent infection and GVHD and, if needed, blood transfusions. If GVHD has not developed by about 120 days post transplant, patients receive additional white cells to boost the immune response. After 100 days, follow-up visits may be less frequent. Follow-up continues

2002 Clinical Trials

8782. Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

. Therefore, newer regimens need to be developed that are more applicable to patients with non-malignant disorders in whom no graft vs. leukemia effect is needed, and where mixed chimerism is sufficient for disease amelioration. In this protocol, we propose transplantation in patients with severe beta-globin disorders including sickle cell disease (SCD), and beta-thalassemia, considered at high risk for complications from or ineligible for standard BMT, with allogeneic PBSCs from an HLA identical sibling (...) (filgrastim, G-CSF) mobilized PBSCs will be used to establish hematopoietic and lymphoid reconstitution. The primary endpoint of this study is treatment success at one year, defined as full donor type hemoglobin on hemoglobin electrophoresis for patients with SCD and transfusion-independence for patients with beta-thalassemia. Other end points include degree of donor-host chimerism necessary for long-term graft survival and disease amelioration, incidence of acute and chronic graft-vs-host disease (GVHD

2003 Clinical Trials

8783. The Effect of Weight Loss and Exercise on Knee Osteoarthritis

Diseases (NIAMS) Information provided by (Responsible Party): Johns Hopkins University Study Details Study Description Go to Brief Summary: This study will evaluate whether a program of weight loss and exercise can help individuals with knee osteoarthritis (OA). Condition or disease Intervention/treatment Phase Osteoarthritis, Knee Behavioral: Behavioral weight control and lifestyle exercise Not Applicable Detailed Description: Knee OA is a major public health challenge affecting millions of people (...) mobility in individuals with knee OA and the ACR Practice Guidelines indicate that it should be included in treatment. Exercise may be especially helpful for overweight persons with knee OA as it is a potent predictor of weight loss maintenance. Though adherence to traditional exercise programs has been poor, adopting lifestyles in which exercise is accumulated throughout the day appears to be a promising new approach to physical activity. Lifestyle exercise may enhance exercise adherence by increasing

2003 Clinical Trials

8784. Study of Mycobacterial Infections

weakness. The study will compare the features of NTM with those of Job syndrome and cystic fibrosis, other diseases involving recurrent infections of the lungs and possibly other organs. Patients with diagnosed or suspected non-tuberculous mycobacterial infection, cystic fibrosis or Job syndrome may be eligible for this study. All participants will have a medical and family history, blood and urine tests, imaging studies that may include X-rays, computed tomography (CT) or magnetic resonance imaging (...) to measure how much air the patient can move into and out of the lungs Body measurements measurements of height, weight, arm span, finger length, etc. Joint function assessment of joint mobility using different maneuvers to test flexibility of joints and ligaments Examination of physical features that might be associated with NTM, such as high arched palate of the mouth, flat feet, or certain skin features Dermatology (skin) examination for reactive skin conditions or other skin problems and possibly

2001 Clinical Trials

8785. A Study of Stem Cells and Filgrastim

Study Description Go to Brief Summary: To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic and functional characteristics as well as the viral load in the stem cells obtained following this procedure. Condition or disease Intervention/treatment Phase HIV Infections Drug (...) : Filgrastim Not Applicable Detailed Description: Patients and volunteers receive seven daily subcutaneous injections of G-CSF. On days 5 and 6 of drug administration, patients have peripheral blood mononuclear cells harvested by leukapheresis. HIV-positive patients are stratified into three cohorts based on CD4 count and presence of symptoms. If no increase in number of harvested stem cells and no grade 4 bone pain toxicity occur in two of the first three patients in a cohort, then the last three patients

1999 Clinical Trials

8786. Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Diseases (ORD). Recruitment status was: Active, not recruiting First Posted : July 6, 2000 Last Update Posted : June 24, 2005 Sponsor: Fairview University Medical Center Information provided by: Office of Rare Diseases (ORD) Study Details Study Description Go to Brief Summary: OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II. Determine (...) Syndrome Hypersensitivity Vasculitis Wegener's Granulomatosis Systemic Lupus Erythematosus Giant Cell Arteritis Pure Red Cell Aplasia Juvenile Rheumatoid Arthritis Polyarteritis Nodosa Autoimmune Thrombocytopenic Purpura Takayasu Arteritis Drug: anti-thymocyte globulin Drug: cyclophosphamide Drug: cyclosporine Drug: filgrastim Drug: methylprednisolone Drug: prednisone Procedure: Autologous Peripheral Blood Stem Cell Transplantation Not Applicable Detailed Description: PROTOCOL OUTLINE: Patients receive

2000 Clinical Trials

8787. Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease

if decompression coring results in a substantial improvement in pain and mobility compared to conservative therapy in patients with avascular necrosis of the hip related to sickle cell disease. Condition or disease Intervention/treatment Phase Bone Avascular Necrosis Sickle Cell Anemia Procedure: Core decompression Not Applicable Detailed Description: PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to stage of avascular necrosis (I vs II vs III). Patients (...) : Completed First Posted : August 4, 2000 Last Update Posted : February 15, 2017 Sponsor: Children's Hospital & Research Center Oakland Information provided by: Children's Hospital & Research Center Oakland Study Details Study Description Go to Brief Summary: OBJECTIVES: I. Phase II trial to determine surgical morbidity of decompression coring, including any adverse events in the perioperative period and the rate of secondary medical or surgical interventions. II. Collect preliminary data to determine

2000 Clinical Trials

8788. Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer

). Patients 18 years of age or older with stage IIIB inflammatory breast cancer that has not metastasized (spread beyond the breast) may be eligible for this study. Candidates are screened with a medical history and physical examination, blood and urine tests, and chest x-ray. They have computed tomography (CT) of the head, chest, abdomen and pelvis as well as a bone scan to determine the extent of disease, and a nuclear medicine scan called MUGA to examine the heart's pumping ability. They may receive (...) a rehabilitation medicine evaluation. Participants undergo the following tests and procedures: Central venous line placement: Patients have a central venous line (plastic tube) placed into a major vein in the chest before beginning treatment. The line remains in the body throughout treatment and is used to give chemotherapy and other medications and to withdraw blood samples. The line is usually placed under local anesthesia in the radiology department or the operating room. Chemotherapy: Patients receive two

1999 Clinical Trials

8789. Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer

, and will not use radiation therapy; or A laboratory-manufactured gene designed to obstruct HIV reproduction will be inserted into the stem cells, rendering future cells that develop from resistance to the virus. Prospective patients will be tested for matching with an HIV-negative donor (family member) and will undergo a medical history, physical examination and several tests (e.g., breathing tests, X-rays, etc.) to determine eligibility for the study. Study participants will then undergo apheresis to collect (...) Neoplasm HIV Infection Drug: GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV Phase 1 Detailed Description: Adult patients with myelodysplasia, leukemia, and non-Hodgkin's lymphoma can be cured by allogeneic bone marrow transplantation (BMT). This curative effect has until now been ascribed to the intense chemoradiotherapy used to condition the recipient for transplantation. The assumption that the curative effect of allogeneic transplantation rests in the ability to deliver very

2000 Clinical Trials

8790. Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

transplantation Procedure: peripheral blood stem cell transplantation Biological: therapeutic allogeneic lymphocytes Drug: cyclosporine Drug: mycophenolate mofetil Other: pharmacological study Other: laboratory biomarker analysis Not Applicable Detailed Description: PRIMARY OBJECTIVES: I. To determine whether stable allogeneic engraftment from unrelated hematopoietic stem cell donors can be safely established using a non-myeloablative conditioning regimen in patients with hematologic malignancies and renal (...) treatable by allogeneic hematopoietic stem cell transplant (HSCT) and all patients with B cell malignancies except those who may be cured by autologous stem cell transplantation (SCT) Age =< 50 years of age with hematologic diseases treatable by allogeneic HSCT who through pre-existing medical conditions or prior therapy are considered to be of high risk for regimen related toxicity associated with a conventional transplant or those patients who refuse a conventional SCT; transplants must be approved

2000 Clinical Trials

8791. Urban African-American Community Hypertension Control

to help close the gap in health status for African Americans. The study was conducted in response to a demonstration and education initiative, "Improving Hypertensive Care for Inner City Minorities", which was reviewed and approved by the Clinical Applications and Prevention Advisory Committee in April 1992 and by the National Heart, Lung, and Blood Advisory Council in May 1992. The Request for Applications was released in October 1992. DESIGN NARRATIVE: The two and a half year intervention trial (...) assigned to a more or less intensive educational-behavioral intervention. Both groups received usual medical care, community HBP education, and HBP patient education materials. In addition, the more intensive group received 1) individualized educational counseling sessions with the CHW to increase understanding of HBP and to address barriers to control of HBP; 2) outreach and follow-up to address inadequate health care resources and health behavior related skills through interim monitoring

2000 Clinical Trials

8792. STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

of complete hematologic response (without progression to accelerated or blastic phase) discontinue treatment on the arm to which they were originally randomized and begin treatment on the other arm. Crossover courses repeat monthly in the absence of progression to accelerated phase or blast crisis, or unacceptable toxicity. Quality of life is assessed prior to study; monthly for the first 6 months of study; at 9, 12, 18, and 24 months; at time of crossover (if applicable); and at treatment discontinuation (...) before year 2 (if applicable). All patients are followed every 3 months for up to 8 years. PROJECTED ACCRUAL: A total of 850 patients (425 per arm) will be accrued for this study. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Primary Purpose: Treatment Official Title: A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph

2000 Clinical Trials

8793. Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

cells. Patients undergo transplantation on day 0, according to applicable transplant protocols, one month after mobilization. Some patients may receive posttransplant interleukin-2 after achieving durable engraftment. Patients are followed at day 30, 80, 180, 365, and 395. PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Primary Purpose: Treatment Official Title: A Phase I (...) : monoclonal antibody CD19 Biological: monoclonal antibody CD20 Procedure: in vitro-treated peripheral blood stem cell transplantation Phase 1 Phase 2 Detailed Description: OBJECTIVES: I. Evaluate the efficiency of tumor cell removal by immunomagnetic technique in patients with B cell malignancies. II. Determine toxicity of mobilized peripheral blood stem cell (PBSC) components of enriched CD34+ and depleted B cells in this patient population. III. Compare recovery with the use of this treatment regimen

1999 Clinical Trials

8794. Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

chemotherapy. Arm ID: 3-Drug Combination Chemotherapy plus Hematologic Toxicity Attenuation. MICE; plus G-CSF. G-CSF during and after chemotherapy. CONSOLIDATION: Arm IIA: 3-Drug Combination Chemotherapy. Mini-ICE. Intravenous IDA/VP-16/ARA-C. Arm IIB: 3-Drug Combination Chemotherapy. Mini-ICE. Oral IDA/VP-16 + subcutaneous ARA-C. Regimen A: Stem Cell Mobilization followed by 4-Drug Combination Myeloablative Chemotherapy with Stem Cell Rescue. G-CSF; followed by BAVC; with PBSC. PROJECTED ACCRUAL: 500 (...) impairment from disease other than AML Hematopoietic: Not applicable Hepatic: Bilirubin less than 2 x ULN Renal: Creatinine less than 2 x ULN Cardiovascular: LVEF at least 50% No severe cardiac disease Pulmonary: No severe pulmonary disease Other: HIV seronegative (if tested) No uncontrolled infection No severe neurologic, metabolic, or psychiatric disease No other concomitant disease that precludes protocol therapy No other progressive malignant disease PRIOR CONCURRENT THERAPY: No prior chemotherapy

1999 Clinical Trials

8795. Study of Mast Cell Precursors

. There is no known cure for any form of the disease. A better understanding of mast cells and how they respond to certain substances may provide insights that will lead to effective treatments for mastocytosis. Patients with systemic mastocytosis and normal healthy volunteers between the ages of 20 and 60 may be eligible for this 8-day study. Participants will undergo the following procedures: Day 1 Medical history, physical examination, and blood tests to assess general health status Days 2 through 6 Daily (...) will be adults of both sexes from 18 to 70 years of age. Granulocyte colony stimulating factor (G-CSF) will be administered to healthy volunteers at dose of 10 mcg/kg/day as a subcutaneous dose daily for 5 days not to exceed 960mcg. Patients will receive Plerixafor at a dose of 0.24 mg/kg as a single subcutaneous dose not to exceed 24mg the night before leukapheresis as a mobilizing agent for CD34+ cells. In identified patients where leukapheresis yield is considered adequate without stimulation

1999 Clinical Trials

8796. Nurse Counseling for Physical Activity in Primary Care Patients

Chronic Disease Exercise Behavioral: Telephone Care Not Applicable Detailed Description: Background: Many elderly primary care patients are at high risk for health complications and functional impairment due to low levels of physical activity. Previous trials of counseling of elderly patients in primary care clinics have not demonstrated lasting physical activity change and have not evaluated fitness changes associated with any increased activity. Objectives: The primary objective was to determine (...) telephone message delivery system; or 3) no follow-up calls. All kept walking diaries and mailed these in to a data collector blinded to intervention group. Follow-up research visits were scheduled at six and 12 months. Self-reported walking, the primary outcome measure, was assessed from the walking diaries and validated by reports of significant others and accelerometer data. Improvement in fitness was assessed at 12 months with a standardized six minute walking test. Tinetti mobility scores, body

2001 Clinical Trials

8797. Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries

evaluations of system performance in these patients. III. Perform long term follow up and monitor system use outside of the laboratory. Condition or disease Intervention/treatment Phase Spinal Cord Injury Procedure: Surgery Device: IRS-8 Not Applicable Detailed Description: PROTOCOL OUTLINE: Patients undergo surgery in which electrodes are sutured into areas of the pelvis and legs. Electrode leads are inserted into a receiver/stimulator implanted in a subcutaneous pocket in the abdomen. Following (...) implantation, patients undergo training in standing, transfers, and other advanced mobility skills using the functional neuromuscular stimulation system. Restricted activity continues for 2 weeks after surgery, followed by 8 weeks of exercise. Standing training then begins, and continues for up to 6 weeks. Home-based training follows prior to discharge with the system for spontaneous use. Patients are followed at 3, 6, and 12 months, then annually thereafter. Study Design Go to Layout table for study

1999 Clinical Trials

8798. The Department of Veterans Affairs Optical Patient Card Workstation. Full Text available with Trip Pro

. The intent of this work is to study the potential benefits of this technology to the VA's distributed health care network, with a large mobile patient population. It is hoped that the use of optical cards and the OPCW will enhance clinicians ability to work with a timely composite health record, and expedite the administrative workload of the medical center. (...) The Department of Veterans Affairs Optical Patient Card Workstation. The Department of Veterans Affairs has developed an optical patient card application which will undergo alpha testing in 1991. The optical cards are carried by patients and contain administrative, clinical, and image information. An optical patient card workstation (OPCW) will read/write these cards and pass this information to the VA Decentralized Hospital Computer Program (DHCP), the VA's health care information system

1991 Proceedings of the Annual Symposium on Computer Application in Medical Care

8799. Transfixation pinning and casting of radial-ulnar fractures in calves: A review of three cases Full Text available with Trip Pro

and judged to be excellent at follow-up evaluation five to nine months later.Advantages of transfixation pinning and casting in management of radial-ulnar fractures include flexibility in pin positioning, adequate maintenance of reduction, early return to weight-bearing status, preservation of joint mobility, and ease of ambulation. The inability to adjust fixation and alignment after cast application is a disadvantage of this technique compared with other external fixators. We concluded (...) Transfixation pinning and casting of radial-ulnar fractures in calves: A review of three cases We reviewed the medical records of three calves with radial-ulnar fractures which were reduced and stabilized by transfixation pinning and casting. Multiple Steinmann pins were placed transversely through proximal and distal fracture fragments and the pin ends were incorporated in fiberglass cast material after fracture reduction. Cast material was placed from proximal to distal radius and served

1992 The Canadian Veterinary Journal

8800. Ticket on the Titanic. Perils and pitfalls of junior faculty development. Full Text available with Trip Pro

Ticket on the Titanic. Perils and pitfalls of junior faculty development. 8754691 1996 09 25 2018 11 13 0008-350X 42 1996 Jul Canadian family physician Medecin de famille canadien Can Fam Physician Ticket on the Titanic. Perils and pitfalls of junior faculty development. 1271-4, 1281-4 Graham J E JE eng fre Editorial Canada Can Fam Physician 0120300 0008-350X IM Adaptation, Psychological Career Mobility Faculty, Medical Humans Job Application Mentors Negotiating Time Management 1996 7 1 1996 7

1996 Canadian Family Physician

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>